Cargando…

A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers

BACKGROUND: SMARCA4, the essential ATPase subunit of SWI/SNF chromatin remodeling complex, regulates transcription through the control of chromatin structure and is increasingly thought to play significant roles in human cancers. This study aims to explore the potential role of SMARCA4 with a view t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Ling, Li, Jisheng, Wu, Jie, Xu, Bin, Wang, Zhiqiang, Giamas, Georgios, Stebbing, Justin, Yu, Zhentao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524462/ https://www.ncbi.nlm.nih.gov/pubmed/34675941 http://dx.doi.org/10.3389/fimmu.2021.762598

Ejemplares similares

A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma
por: Zhu, Liping, et al.
Publicado: (2021)

Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution
por: Stebbing, Justin, et al.
Publicado: (2011)

The many-faced KSR1: a tumor suppressor in breast cancer
por: Zhang, Hua, et al.
Publicado: (2015)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
por: Rani, Aradhana, et al.
Publicado: (2019)

A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas
por: Dai, Lei, et al.
Publicado: (2022)

Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer
por: Angelopoulos, Nicos, et al.
Publicado: (2016)

High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer
por: Guerrero-Martínez, Jose A., et al.
Publicado: (2018)

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
por: Cantley, Jennifer, et al.
Publicado: (2022)

Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer
por: Zhang, Hua, et al.
Publicado: (2015)

A pyroptosis‐related lncRNA signature in bladder cancer
por: Wang, Peng, et al.
Publicado: (2022)

Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics
por: Stebbing, Justin, et al.
Publicado: (2015)

Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas
por: Urer, Halide Nur, et al.
Publicado: (2023)

Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
por: Lin, Yun-Tzu, et al.
Publicado: (2023)

A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
por: Fang, Hui, et al.
Publicado: (2022)

The SMARCA4(R1157W) mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer
por: Zeng, Xiangwei, et al.
Publicado: (2023)

Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis
por: Liu, Peng, et al.
Publicado: (2022)

Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer
por: Guo, Qijing, et al.
Publicado: (2023)

A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing data
por: Du, Zhonghai, et al.
Publicado: (2023)

circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer
por: Cai, Juan, et al.
Publicado: (2019)

Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis
por: Tu, Zewei, et al.
Publicado: (2022)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

The Emerging Roles of circSMARCA5 in Cancer
por: Qin, Haoyu, et al.
Publicado: (2022)

Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type
por: Jelinic, Petar, et al.
Publicado: (2016)

Pan-cancer analyses of classical protein tyrosine phosphatases and phosphatase-targeted therapy in cancer
por: Wang, Tao, et al.
Publicado: (2022)

A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy
por: Xu, Bingxiang, et al.
Publicado: (2021)

Response to: Comment on “circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer”
por: Cai, Juan, et al.
Publicado: (2019)

Complex Alternative Splicing of the Smarca2 Gene Suggests the Importance of Smarca2-B Variants
por: Yang, Min, et al.
Publicado: (2011)

Thoracic SMARCA4-deficient undifferentiated tumor
por: Jiang, Jiapeng, et al.
Publicado: (2023)

Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
por: Leitner, Katharina, et al.
Publicado: (2020)

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients
por: Armon, Subasri, et al.
Publicado: (2021)

Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
por: Liu, Jian-Nan, et al.
Publicado: (2020)

A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor
por: Mo, Zhuomao, et al.
Publicado: (2021)

Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer
por: Zhong, Hongguang, et al.
Publicado: (2023)

Clinical characteristics and prognostic analysis of SMARCA4‐deficient non‐small cell lung cancer
por: Liang, Xiyue, et al.
Publicado: (2023)

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis
por: Chen, Rui, et al.
Publicado: (2022)

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
por: Zhang, Xinke, et al.
Publicado: (2021)

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
por: Cheng, Xin, et al.
Publicado: (2021)

MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis
por: Zhong, Chenming, et al.
Publicado: (2022)

NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy
por: Xia, Jiaqi, et al.
Publicado: (2021)

A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
por: Gao, Zijie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4bj2mslbav6hm43u5bmnkig4kd